Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
152 papers
This study reviewed surveys and used global models to measure how the COVID-19 pandemic changed rates of major depressive disorder and anxiety disorders in 2020. It found that places with higher COVID-19 infection rates and bigger drops in movement had larger increases in these disorders. The authors estimate about 53.2…
In a small, carefully controlled study, seven people with major depression each received a single low-dose ketamine infusion on one day and a saline infusion on another day, without anyone knowing which was which. People who got ketamine showed clear improvement in their depressive symptoms within three days, while those…
In a small, controlled study of 18 people with treatment-resistant major depression, a single intravenous dose of the NMDA receptor antagonist ketamine (0.5 mg/kg) produced rapid drops in depression scores. Improvement began within about 2 hours and remained statistically significant compared with placebo for up to 1 week. The study…
This small randomized trial tested a fully automated text-based conversational agent called Woebot as a way to deliver cognitive behavioral therapy to college-age young adults with symptoms of depression and anxiety. Over 2 weeks, the Woebot group (n=34) showed a statistically larger drop in depression scores (PHQ-9) than an information-only…
This study reviewed systematic reviews to measure death risks in major mental disorders. The authors screened 407 reviews and found 20 that reported mortality risks for 20 different disorders, covering over 1.7 million patients and more than a quarter of a million deaths. Every disorder showed higher all-cause death rates…
This 2001 review looked at studies on exercise, anxiety, depression, and stress. It found that short-term emotional effects of exercise are mixed, but many cross-sectional and longitudinal studies report that regular aerobic exercise training reduces anxiety and depression symptoms and may protect against the harmful effects of stress. The clearest…
This study followed 1,604 U.S. adults older than 60 for six years. It found that people who said they felt lonely (43% of the group) were more likely to have worse day-to-day function and were more likely to die. After the researchers adjusted for age, wealth, living situation, depression, and…
Researchers tested a single intravenous dose of ketamine in 73 people with major depression that had not gotten better with usual treatments. In a two-site, double-blind trial, people were randomly given either ketamine or an active placebo (the anesthetic midazolam). Twenty-four hours after the infusion, people who got ketamine were…
This review pooled studies from 2007–2018 to measure how strongly burnout is related to depression and to anxiety. The authors found a moderate positive link with depression (r = 0.52) and a moderate link with anxiety (r = 0.46). They also report that measurement choice and study quality changed the…
This 12-week randomised trial tested a structured dietary program (a modified Mediterranean-style diet) against a social-support control in adults with moderate to severe major depression. Sixty-seven people were randomised (33 to diet, 34 to control). The diet group showed larger drops in depressive symptoms on the MADRS scale at 12…
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
Researchers tested a nasal spray form of esketamine together with a newly started oral antidepressant in adults whose depression had not improved after trying at least two antidepressants. Over four weeks, people who got esketamine plus a new antidepressant had faster and larger drops in depression symptoms than those who…
